Frovatriptan contraindications: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Frovatriptan}} {{CMG}}; {{AE}} {{SS}} ==Contraindications== FROVA is contraindicated in patients with: *Ischemic coronary artery disease (CAD) (e.g. angina pecto...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Contraindications== | ==Contraindications== | ||
FROVA is contraindicated in patients with: | FROVA is contraindicated in patients with: | ||
| Line 20: | Line 21: | ||
*Recent use (i.e., within 24 hours) of another 5-HT1 agonist, an [[ergotamine]] containing or ergot-type medication such as [[dihydroergotamine]] ([[DHE]]) or [[methysergide]] [see Drug Interactions (7.1, 7.2)]. | *Recent use (i.e., within 24 hours) of another 5-HT1 agonist, an [[ergotamine]] containing or ergot-type medication such as [[dihydroergotamine]] ([[DHE]]) or [[methysergide]] [see Drug Interactions (7.1, 7.2)]. | ||
*[[Hypersensitivity]] to FROVA (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)]. | *[[Hypersensitivity]] to FROVA (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0703630-9ce8-4259-841e-71fd2019fa66 | publisher = | date = | accessdate = 7 February 2014 }}</ref> | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c0703630-9ce8-4259-841e-71fd2019fa66 | publisher = | date = | accessdate = 7 February 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 22:26, 9 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
FROVA is contraindicated in patients with:
- Ischemic coronary artery disease (CAD) (e.g. angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal’sangina [see Warnings and Precautions (5.1)].
- Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)].
- History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)].
- Peripheral vascular disease [see Warnings and Precautions (5.5)].
- Ischemic bowel disease [see Warnings and Precautions (5.5)].
- Uncontrolled hypertension [see Warnings and Precautions (5.8)].
- Recent use (i.e., within 24 hours) of another 5-HT1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1, 7.2)].
- Hypersensitivity to FROVA (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].[1]
References
- ↑ "FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED [ENDO PHARMACEUTICALS INC.]". Retrieved 7 February 2014.